The promise of gene therapy began with the identification of single genes responsible for autosomal recessive disorders like cystic fibrosis (CF) and alpha-1 antitrypsin (AAT) deficiency, and with the development of gene transfer vectors based on viruses capable of in vivo DNA transfer and gene expression. Over time, positive results from proof-of-concept studies in cell culture and animal models and the accumulation of preclinical safety data has led to the initiation of phase I and II clinical trials of recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR and rAAV2-AAT gene therapy vectors. As these trials have progressed, much attention has been focused on potential safety issues, such as insertional mutagenesis, inadvertent germ line transmission, and immune responses to vector components and transgene products. To date, over 140 CF patients and 8 AAT deficient patients have been safely treated with rAAV2 vectors. No dramatic therapeutic benefits have yet been observed. However, important new information has been gained from both clinical and preclinical studies, which has informed the development of new vector strategies based on alternate rAAV serotypes. Simultaneously, gene transfer experiments have led to an improved understanding of the pathogenesis of the complex phenotypes associated with these disorders.
AAV AND RECOMBINANT AAV VECTORS
AAV is one of a relatively small group of viruses that have been successfully modified for use as gene transfer agents in human trials (1) (2) (3) (4) (5) (6) (7) (8) . The properties of AAV that make it potentially useful for therapeutic gene transfer are listed in Table 1 . AAV is a 20-nm diameter replication-deficient parvovirus ( Fig. 1) native to humans and nonhuman primates and exists in nature in over 100 distinct variants, including both those defined serologically as serotypes and those defined by DNA sequence as genomovars (9 -10) . There is no consistent indication of AAV infection being associated with human disease, although adverse effects on early embryos have been suggested from ex vivo studies. Interestingly, many of the AAV serotypes have distinct cell and tissue affinities, potentially creating the option for generating a variety of different vector classes from this one genus of virus.
The life cycle of AAV has been studied in detail (11) (12) . Cells infected with AAV require a helper virus, such as an adenovirus, herpesvirus, or vaccinia virus, to replicate efficiently in cell culture. Cells infected with AAV alone usually harbor AAV genomes in a persistent or latent state. Latent AAV genomes exist in a number of forms including episomal forms, randomly integrated forms, and forms that are integrated site-specifically into a region of human chromosome 19 known as the AAVS1 site (13) (14) (15) (16) (17) (18) . The 4.7 kb AAV genome mediates all of these functions with only 2 genes, the cap gene, which encodes the 3 AAV capsid proteins, and the rep gene, which encodes the four nonstructural Rep proteins, which are required for viral replication and site-specific integration. Flanking the AAV genes are the inverted terminal repeats (ITRs), which contain the cis-acting sequences required for DNA replication and packaging. Sequences within the ITR also have transcription regulatory activity, including enhancer function and a low efficiency promoter function.
Recombinant AAV vectors based on the most frequently studied serotype, AAV2, were produced in the mid-1980s by creating ITR-deleted helper plasmids to supply rep and cap functionsm (19 -21) . Recombinant AAV2 vector plasmids were also constructed in which ITR-sequences flanked the therapeutic gene of interest, along with an appropriate promoter and polyadenylation signal. When helper plasmids and vector plasmids were co-transfected into permissive cells (usually human embryonic kidney 293 cells) that were also infected with a helper adenovirus, those cells packaged rAAV2 virions containing only the therapeutic vector genomes. Vector particles, thus produced, could be purified using CsCl density gradient ultacentrifugation. Over time, rAAV2 packaging and purification technology has improved, and helper plasmids now most frequenly encode both adenovirus and AAV helper genes. Recombinant vector particles are often purified using column chromatography methods and/or nonionic gradient media, resulting in a higher level of infectivity of recombinant virus as well as higher overall titers (22) .
RECOMBINANT AAV2 VECTORS FOR CYSTIC FIBROSIS (CF) GENE THERAPY
CF was one of the first human diseases targeted for gene therapy with rAAV vectors. Early work focused on defining small endogenous promoter elements within the left-hand end of the AAV genome that could be used to express the relatively large coding sequence of the CF transmembrane conductance regulator (CFTR) gene (4.44kb) within the limited packaging capacity of this small virus (approximately 5kb packaging limit) (23) (24) . Since 0.3 kb was required for the two AAV2-ITRs, there was relatively little space available for exogenous promoter elements. Vectors expressing reporter genes or CFTR from compact elements in or near the AAV2-ITR were produced and shown to mediate the typical cAMP-activated chloride currents characteristic of CFTR expression ( Fig. 2) , as well as restoring regulation of other ion channels in airway epithelial cells, such as the outwardly rectifying chloride channel (25) .
Preclinical studies demonstrated that rAAV vectors were capable of long-term gene transfer and expression in the bronchial epithelium of rabbits and nonhuman primates, despite the fact that vector genomes appeared to persist predominantly in the episomal state (26 -29) . Importantly, studies also demonstrated no increase in inflammatory cells, or proinflammatory cytokines after rAAV delivery to the lower airways of nonhuman primates. Likewise, there were no adverse changes in chest x-rays, arterial blood gases, or pulmonary function tests in these animals after rAAV delivery. Based on this information, a number or phase I and phase II clinical trials of rAAV2-CFTR were performed.
Phase I clinical trials of rAAV2-CFTR included studies of nasal and endobronchial instillation, direct instillation into the 1144 FLOTTE maxillary sinuses, and aerosol inhalation (1) (2) (3) (4) (5) (6) (7) (8) . These studies showed definite evidence of dose-related DNA transfer, and some indication of gene expression. Subsequent phase II studies of aerosol inhalation of rAAV2-CFTR have indicated again that gene transfer and its effects are detectable for approximately 30 d after the initial instillation (Fig. 3) . Altogether over 200 CF patients participated in these trials, with over 140 receiving active vector. There was no consistent indication of vector-related adverse effects from any of these studies. Unfortunately, neutralizing antibodies were also detected and repeated doses did not show evidence of repeated efficient gene transfer. The shorter duration of gene transfer in the human studies may be due to an accelerated turnover of bronchial epithelium in the context of the diseased CF lung.
During the course of these studies a number of key limitations of the rAAV2-CFTR vector technology came to light, some from these studies directly and others from the work of other investigators. Some of these key limitations are listed in Table 2 . The efficiency of gene transfer and expression appear to have been limited by the relatively low abundance of the typical AAV2 receptor (heparan sulfate proteoglycan) and its co-receptors (alphaV-beta5 integrin, and FGF-receptor) on the apical surface of the airways and by the relative inefficiency of the AAV-ITR promoter (30 -32) . Both of these were relative limitations, however, as indicated by recent data from a tracheal xenograft model in which an alternative receptor pathway that is more susceptible to proteasome-mediated degradation has been defined (33) . When this pathway is blocked, the efficiency of gene transfer with the original rAAV2-ITRpromoter driven vector was comparable with newer vectors. Nonetheless, this inefficiency was compounded by inactivation of rAAV2 particles by extracellular barriers, including neutrophil elastase, neutrophil-derived alpha defensins, and other substances (34) . The ultimate problem, however, appears to have been the short duration of gene transfer, which apparently related to the more rapid turnover of the CF airway epithelium with the subsequent loss of episomal rAAV genomes. The development of neutralizing antibodies by patients in these studies correlated with an inability to observe repeated positive results with repeated administrations of the vector.
DEVELOPMENT OF THE NEXT GENERATION OF
rAAV-CFTR: rAAV5-CB-dl264 CFTR Based on the information gleaned from these trials and other developments in the field, newer generations of rAAV-CFTR have been developed by a number of groups. One such agent combines the newly available serotype 5 capsid (actually a pseudotype, since the AAV2-ITRs are present in the vector DNA cassette), a large very efficient CMV/beta actin (CB) hybrid promoter, and a minigene version of CFTR that omits sequences that are not necessary for cAMP-activated chloride channel activity (35) . The serotype 5 capsid targets alternative receptors present in higher abundance in the CF airways, and may avoid neutralizing antibodies to AAV2. The more active promoter will assure a greater level of mRNA expression within each transduced cell, while the CFTR minigene allows sufficient capacity within the vector for the promoter to be efficiently packaged.
Recently published studies with the rAAV5-CB-dl264CFTR indicate that it is capable of high level expression of CFTR chloride currents in cell lines, and ameloriation of the lung inflammation and weight loss phenotypes of CFTR knock-out mice that are exposed to a Pseudomonas-agarose bead slurry (Fig. 4) . This vector type also has shown an increase in the efficiency of gene transfer in larger animal models. 
RECOMBINANT AAV VECTORS FOR GENE THERAPY OF AAT DEFICIENCY
One of the key limitations of rAAV vectors learned from the preclinical and clinical studies associated with the CF gene therapy effort, was the finding that the majority of vector genomes were episomal, thus limiting their persistence in the steadily proliferating CF bronchial epithelium. Diseases due to deficiencies of secreted proteins might not share that problem, however, since nonproliferating cells might be targeted for gene transfer. One such disease of interest is alpha-1 antitrypsin (AAT) deficiency. The frequency of AAT mutation in the population is similar to that seen with CF, approximately 4%. AAT deficiency is more genetically homogeneous than CF, however, with Ͼ95% of mutant alleles being represented by the so-called Z allele. This missense mutation leads to a defect in secretion of this important 52kD antiprotease from hepatocytes into the circulation. A lack of AAT results in long-term loss of pulmonary interstitial elastin, due to the unopposed action of neutrophil elastase and other neutrophil products. The loss of interstitial elastin and chronic airway inflammation lead to a form of chronic obstructive pulmonary disease that is typically diagnosed in adulthood. Genotype-phenotype and protein replacement experience suggests that lung disease risk is much reduced if plasma AAT levels are above 11 micromolar (570 -800 g/mL; 57-80 mg/dL) (36) . The goal of gene therapy for AAT lung disease is, therefore, to substitute for protein replacement in expressing levels in that range.
The potential utility of rAAV2-mediated transduction of skeletal muscle as a site for ectopic AAT secretion was described in a number studies from the late 1990s in which the biologic efficacy of rAAV2 vectors and the efficiency of secretion were noted (37) (38) (39) (40) demonstrated that a single IM dose of rAAV2-AAT in C57Bl6 mice resulted in levels of AAT that would be therapeutic in humans (Fig. 5) . Interestingly, C57Bl6 mice were tolerant for human AAT, while many other mouse strains were not, apparently due to immunologic differences. Even more serendipitous was the observation that another immunologic control strain for these experiments, a DNAdependent protein kinase (DNA-PK)-deficient severe combined immune deficiency (SCID) mouse model was also readily transduced by rAAV2-hAAT, but resulted in a predominance of integrated vector forms long-term (41) . This stood in contrast to C57Bl6 mice, which demonstrated predominantly episomal persistence. This finding was later reproduced with liver delivery of rAAV2-AAT (42) . The latter approach had the added feature of allowing for more sensitive and specific differentiation between episomal and integrated forms. Further data indicated in a cell-free system, that DNA-PK, a critical component of the ligase used for DNA double-strand break repair and VDJ recombination both inhibited rAAV2 integration and promoted the formation of episomal vector-to-vector junctions.
These studies not only established the proof-of-concept for IM rAAV2-AAT gene therapy trials in humans, but also pointed out that the episomal pool of vector genomes that predominates with rAAV2 vectors is formed by an active process that requires the activity of host cell factors, like DNA-PK. Further preclinical studies were performed in C57Bl6 mice and New Zealand White rabbits to better define the potential for inadvertent germline transmission or other vector-related adverse effects (43) . Based on that information a phase I study of rAAV2-AAT IM injection in C57Bl6 mice has been initiated. This ongoing study will include doses up to approximately 7 ϫ 10 13 vector genomes per patient (7) . At the same time, critical proof-of-concept and safety data are being generated with a rAAV1-pseudotyped rAAV-AAT vector, a vector which mediates 500-fold greater gene transfer efficiency in recent studies (44) .
SUMMARY AND FUTURE DIRECTIONS
The development of rAAV2 vectors for CF and AAT deficiency has resulted in a number of key findings, including an excellent safety record through experience with over a thousand animals and nearly 150 human patients. In addition to the short-term safety of this class of vector, an important series of studies suggest that the risk of insertional mutagenesis with this vector class is likely to be smaller than that seen with retrovirus vectors, since the majority of rAAV genomes are episomal and since this episomal persistence is mediated by a specific DNA-PK dependent host-cell pathway. The efficacy data with rAAV2 vectors has been more modest. However, the advent of newer rAAV serotypes has opened the possibility that lessons learned from the early years of CF and AAT gene therapy will be salient to the development of later generations of AAV vectors that have enhanced efficacy, while retaining the important safety features of this vector.
Recent years have also witnessed an extensive expansion of the use of these vectors to other diseases, particularly genetic and metabolic disorders involving the muscle, liver, and CNS. Recombinant AAV vectors have also been used to model and complement important animal models that better mimic the human phenotypes of these disorders. The combination of better animal models and improved biologic efficacy support the concept that in the future, safe and effective rAAVmediated gene transfer methods will be devised. 
